Lidocaine Infusion in Pancreatic Cancer

This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will be used for the proposed study.

Trial Details

NCT ID
NCT04048278
Phase
EARLY_PHASE1
Sponsor
University of Illinois at Chicago
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Lidocaine Hydrochloride
  • Saline Solution for Injection
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Has histologically or cytologically confirmed adenocarcinoma of the pancreas that is considered resectable as well as other types of pancreatic can…
  • Has measurable disease, defined as at least 1 tumor that fulfills the criteria
  • Patients diagnosed with resectable cancer, but upon initial phase of surgical exploration found to have metastatic disease
  • Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Independent Ethics Committee (IRB/IEC)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →